The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. [Operator Instructions]. I will now ...